Association between inhaled long-acting beta-2-agonists and the risk of acutemyocardial infarction: A methodological comparison of two databases
Afonso, Ana S.M.; Schmiedl, Sven; Becker, Claudia; Primatesta, Paola; Plana, Estel; Souverein, Patrick C.; Korevaar, Joke C.; Hasford, Joerg; Reynolds, Robert; De Groot, Mark C.H.; Schlienger, Raymond G.; Klungel, Olaf H.; Rottenkolber, Marietta
(2014) Pharmacoepidemiology and Drug Safety, volume 23, issue S1, pp. 390 - 391
(Abstract)
Abstract
Background: Results from multiple observational studies on inhaled long-acting beta-2-agonists (LABA) and the risk of acute myocardial infarction (AMI) are conflicting, due to variations in methodological, clinical and health care characteristics. To some extent, the discrepancies in the design might limit the comparability of the results encountered. Objectives: To determine
... read more
the risk of AMI in inhaled LABA users in two European electronic primary care databases using a common study protocol. Methods: Patients from the Dutch Mondriaan (1.4 Million) and the UK CPRD (5 Million) databases were included if they had a diagnosis of asthma and/or COPD, and were prescribed at least one inhaled LABA, a short-acting beta-2-agonist (SABA), or a short- or long-acting muscarinic antagonist (SAMA, LAMA) during the study period (2002 to 2009). LABA episodes were divided into current, recent (
show less
Download/Full Text
Embargo until January 01 2050
Keywords: beta 2 adrenergic receptor stimulating agent, muscarinic receptor blocking agent, risk, infarction, data base, pharmacoepidemiology, risk management, human, patient, asthma, implantable cardioverter defibrillator, prescription, drug therapy, primary medical care, potential difference, health care, acute heart infarction, morbidity, model, proportional hazards model, diagnosis, United Kingdom, confidence interval, hazard ratio, observational study
ISSN: 1053-8569
Publisher: John Wiley and Sons Ltd
Note: Special Issue: Abstracts of the 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, October 24–27, 2014, Taipei, Taiwan